pm360online.com/allocating-cov… , risk is also socioeconomic

Join today at noon EST ptechealth.org/events discussion of equity in health system design and administration

Our first panel of the day will begin at 11:15 AM ET on "State Price Controls for #Pharmaceutical Products" featuring Kirsten Axelsen (she/her) (American Enterprise Institute), @skaminerd (Patients For Affordable Drugs NOW), Peter Maybarduk (Public Citizen) and Steven Horwitz (Ball State University)

Join us for Dr. Jay Bhatt and Christina Floyd on Feb 22nd noon EST ptechealth.org/events focus on data collection and information for greater equity in healthcare delivery

Who needs the Oscars when you have American Enterprise Institute recommending film and television aei.org/economics/aeis…

The #ACA expanded insurance coverage requirements for preventive care services and included other provisions intended to increase their use. However, in a new American Enterprise Institute report, Kirsten Axelsen (she/her), Kieran Allsop, and Sara Rogers show the use of these services has declined: aei.org/research-produ…

podcasts.apple.com/us/podcast/the… #iTunes

New Research Proposes Metrics, Measures, and Models Promoting Health Equity via @ptechealth and AcademyHealth shar.es/aWZwgp

Future of Healthcare Summit: Tackling Costs thehill.com/event/579612-f…

aei.org/economics/drug… on AEIdeas

crai.com/insights-event…

Join me on 5/23 for a KFF virtual conversation on what the Biden Administration could do to address drug affordability. With other experts, we’ll explore the drivers of rising prescription drug prices and potential administrative actions to address them. us02web.zoom.us/webinar/regist…

Price controls on medicines save money for the federal government, but not necessarily for consumers washex.am/3bh1zIr

Excited to read this analysis of the IRA’s potential impact on cancer drug R&D — including the detailed, transparent methods! crai.com/insights-event…

There is a pressing need for robust evidence to inform biopharmaceutical policy, Kirsten Axelsen (she/her) and co-authors write in Health Affairs Scholar. The article is part of a new series that explores financial rewards for new drugs and R&D investment. Information Technology and Innovation Foundation bit.ly/48gciw8

If we import other countries' drug policy we also import their outcomes ... biospace.com/policy/opinion…

The IRA And Post-Approval Clinical Research For Cancer Medicines aei.org/articles/the-i…

Coverage of Obesity Medications Can Make America Healthier (Again) realclearhealth.com/blog/2024/12/2…

Join Incubate and DLA Piper during #JPM2025 for a #biopharma and #healthpolicy panel featuring Nina Kjellson, Kirsten Axelsen (she/her), John Stanford, and Gaurav Gupta. RSVP here: eventbrite.com/e/the-outlook-…

As some #IRA provisions take effect for the first time in 2025, a DLA Piper assessment of how the number and types of #Medicare plans changed over the last three years poses potential considerations for policy makers: spr.ly/6010xi4y2 #LifeSciences #Insurance #Healthcare